177Lu-PSMA-617 SPECT/CT早期预测转移性去势抵抗性前列腺癌总生存
本研究为ENZA-p试验的二次分析,纳入74例接受恩扎卢胺联合177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者,于6周时行SPECT/CT定量评估肿瘤总体积(TTV)。TTV完全缓解(CR,定义为第2周期TTV小于1 mL)与更好的总生存相关(2年生存率83% vs 67%;
要点
- 6周TTV CR定义为第2周期TTV小于1 mL,与总生存改善独立相关。
- TTV CR与深度PSA反应联合可进一步分层预后。
关键影像表现/征象
- 基线中位TTV为236 mL(IQR 81-688 mL),6周时降至65 mL(IQR 12-215 mL)。
- TTV中位变化为-57%(IQR -89%至-38%),4.1%(3/74)出现TTV增加。
诊断标准与关键数值
- TTV完全缓解(CR)定义为第2周期SPECT/CT上TTV小于1 mL,16%(12/74)达到。
- 深度PSA反应定义为第2周期PSA下降90%或以上,63%(45/71)达到。
临床应用与阅片要点
- 可在177Lu-PSMA-617治疗6周时通过SPECT/CT定量TTV评估早期反应,辅助预后分层。
局限性
- 本研究为二次分析,样本量有限(74例),需进一步验证。
- TTV CR定义(<1 mL)及阈值来源于本试验,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Lutetium 177 (177Lu) prostate-specific membrane antigen (PSMA)-617 SPECT/CT has demonstrated promise as a response biomarker for 177Lu-PSMA-617 therapy. Purpose To predict overall survival (OS) after enzalutamide plus 177Lu-PSMA-617 using quantitative parameters at 177Lu-PSMA-617 SPECT/CT at 6 weeks, as well as prostate-specific antigen (PSA) response, in participants with metastatic castration-resistant prostate cancer. Materials and Methods This secondary analysis of the multisite prospective ENZA-p trial (August 2020-July 2022) included participants who received enzalutamide plus 177Lu-PSMA-617 (7.5 GBq). SPECT/CT was performed 24 hours after each treatment, and total tumor volume (TTV) and mean standardized uptake value were compared between the first (baseline) and second (6-week) doses. TTV complete response (CR) at SPECT/CT was defined as TTV less than 1 mL at dose 2, and deep PSA response was defined as 90% or greater PSA reduction at dose 2. Relationships between TTV CR and deep PSA response at dose 2 and OS were examined. Results This analysis included 74 men (median age, 71 years [IQR, 66-78 years]). Median follow-up was 33 months (95% CI: 28, 37). Median OS was 31 months (95% CI: 25, 33), and the 2-year survival rate was 70% (95% CI: 58, 79). Median TTV was 236 mL (IQR, 81-688 mL) at baseline and 65 mL (IQR, 12-215 mL) at 6 weeks. Median change in TTV was -57% (IQR, -89% to -38%); 4.1% (three of 74) of participants had an increase in TTV, and 16% (12 of 74) had TTV CR. Deep PSA response was seen in 63% (45 of 71) of participants. The 2-year survival rate with TTV CR was 83% (95% CI: 48, 96), versus 67% (95% CI: 54, 77) without TTV CR (hazard ratio, 0.26 [95% CI: 0.08, 0.85]; log-rank P = .02). The 2-year survival rate was 76% (95% CI: 58, 87) with deep PSA response without TTV CR (log-rank P = .05 vs TTV CR) and 54% (95% CI: 33, 71) with neither deep PSA response nor TTV CR (log-rank P = .003 vs TTV CR). Conclusion TTV CR at 177Lu-PSMA-617 SPECT/CT at 6 weeks was associated with improved OS and may be a valuable tool for treatment personalization with 177Lu-PSMA-617. ClinicalTrials.gov Identifier: NCT04419402 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Galgano and Turner in this issue.
引用
- Ayati N, Papa N, Crumbaker M, et al. 177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Radiology. 2026. PMID: 42048586. doi:10.1148/radiol.252672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。